JP2013543481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543481A5 JP2013543481A5 JP2013517506A JP2013517506A JP2013543481A5 JP 2013543481 A5 JP2013543481 A5 JP 2013543481A5 JP 2013517506 A JP2013517506 A JP 2013517506A JP 2013517506 A JP2013517506 A JP 2013517506A JP 2013543481 A5 JP2013543481 A5 JP 2013543481A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- surfactant
- preparation
- agent
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 33
- 239000013078 crystal Substances 0.000 claims 24
- 239000000243 solution Substances 0.000 claims 19
- 238000004519 manufacturing process Methods 0.000 claims 16
- 239000004094 surface-active agent Substances 0.000 claims 16
- 239000000725 suspension Substances 0.000 claims 14
- -1 1,2-benzisothiazol-3-yl Chemical group 0.000 claims 12
- 239000007864 aqueous solution Substances 0.000 claims 12
- 239000003405 delayed action preparation Substances 0.000 claims 12
- 238000002360 preparation method Methods 0.000 claims 12
- 239000004480 active ingredient Substances 0.000 claims 11
- 238000002425 crystallisation Methods 0.000 claims 11
- 230000008025 crystallization Effects 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- 239000003960 organic solvent Substances 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000006172 buffering agent Substances 0.000 claims 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- HUXSAESWQBPYHL-UHFFFAOYSA-N azecane-2,10-dione Chemical compound O=C1CCCCCCCC(=O)N1 HUXSAESWQBPYHL-UHFFFAOYSA-N 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 6
- 239000004359 castor oil Substances 0.000 claims 6
- 235000019438 castor oil Nutrition 0.000 claims 6
- 238000001914 filtration Methods 0.000 claims 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 6
- 239000007951 isotonicity adjuster Substances 0.000 claims 6
- 239000012046 mixed solvent Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000008215 water for injection Substances 0.000 claims 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003981 vehicle Substances 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 2
- 238000011049 filling Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229960003194 meglumine Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 2
- 229920001993 poloxamer 188 Polymers 0.000 claims 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- 239000012929 tonicity agent Substances 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940001593 sodium carbonate Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 235000011008 sodium phosphates Nutrition 0.000 claims 1
- 239000008174 sterile solution Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39406910P | 2010-10-18 | 2010-10-18 | |
| US61/394,069 | 2010-10-18 | ||
| PCT/JP2011/074375 WO2012053654A1 (en) | 2010-10-18 | 2011-10-18 | Sustained-release formulation for injection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016033019A Division JP6173502B2 (ja) | 2010-10-18 | 2016-02-24 | 注射用徐放性製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543481A JP2013543481A (ja) | 2013-12-05 |
| JP2013543481A5 true JP2013543481A5 (https=) | 2014-12-04 |
| JP5893616B2 JP5893616B2 (ja) | 2016-03-23 |
Family
ID=45933169
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013517506A Expired - Fee Related JP5893616B2 (ja) | 2010-10-18 | 2011-10-18 | 注射用徐放性製剤 |
| JP2016033019A Expired - Fee Related JP6173502B2 (ja) | 2010-10-18 | 2016-02-24 | 注射用徐放性製剤 |
| JP2017131059A Expired - Fee Related JP6410889B2 (ja) | 2010-10-18 | 2017-07-04 | 注射用徐放性製剤 |
| JP2018179030A Pending JP2019006822A (ja) | 2010-10-18 | 2018-09-25 | 注射用徐放性製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016033019A Expired - Fee Related JP6173502B2 (ja) | 2010-10-18 | 2016-02-24 | 注射用徐放性製剤 |
| JP2017131059A Expired - Fee Related JP6410889B2 (ja) | 2010-10-18 | 2017-07-04 | 注射用徐放性製剤 |
| JP2018179030A Pending JP2019006822A (ja) | 2010-10-18 | 2018-09-25 | 注射用徐放性製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9469630B2 (https=) |
| EP (1) | EP2629775A4 (https=) |
| JP (4) | JP5893616B2 (https=) |
| KR (1) | KR101936968B1 (https=) |
| CN (3) | CN107595771A (https=) |
| CA (1) | CA2814840C (https=) |
| WO (1) | WO2012053654A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| WO2014084921A1 (en) * | 2012-11-27 | 2014-06-05 | Rose Stuart | Pharmaceutical manufacturing method and compositions |
| WO2014152562A1 (en) * | 2013-03-15 | 2014-09-25 | Epizyme, Inc. | Injectable formulations for treating cancer |
| TW201609145A (zh) * | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | 注射劑及形成緩釋（ｄｅｐｏｔ）之方法 |
| WO2016044649A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Injectable formulations for treating cancer |
| KR101792414B1 (ko) * | 2016-05-19 | 2017-11-01 | 삼성전기주식회사 | 박막 커패시터 및 그 제조방법 |
| CN105963253A (zh) * | 2016-06-19 | 2016-09-28 | 朱武欣 | 一种罗替戈汀长效水性混悬型注射剂 |
| WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| CA3034995A1 (en) * | 2016-08-31 | 2018-03-08 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous suspension preparation |
| US10252229B2 (en) * | 2017-06-30 | 2019-04-09 | Snowie LLC | System comprising a pump attached to a tank casing for mixing a fluid |
| SG11202008233WA (en) | 2018-02-28 | 2020-09-29 | Sumitomo Dainippon Pharma Co Ltd | Aqueous suspension pharmaceutical preparation with controlled dissolution |
| SG11202008204QA (en) * | 2018-02-28 | 2020-09-29 | Sumitomo Dainippon Pharma Co Ltd | Aqueous suspension pharmaceutical preparation |
| JP7214103B2 (ja) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | 遊技機 |
| JP7214100B2 (ja) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | 遊技機 |
| JP7214102B2 (ja) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | 遊技機 |
| JPWO2020179925A1 (https=) * | 2019-03-07 | 2020-09-10 | ||
| CN110478131B (zh) * | 2019-08-05 | 2022-01-11 | 思必康（厦门）新材料有限公司 | 一种pH响应变色的纱布及其制备方法和该纱布的应用 |
| US11041740B1 (en) | 2019-12-20 | 2021-06-22 | EmpNia Inc. | Method and apparatus for real time respiratory gating signal generation and detection of body deformation using embedded fiber Bragg gratings |
| CN119431400A (zh) * | 2020-03-27 | 2025-02-14 | 波士顿科学国际有限公司 | 用于使药物结晶的方法 |
| EP4196106A1 (en) * | 2020-08-11 | 2023-06-21 | Auxilla Pharmaceuticals and Research LLP | A non-aqueous suspension of anticancer agent |
| US11992559B2 (en) | 2021-02-24 | 2024-05-28 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
| JP2024511693A (ja) | 2021-03-31 | 2024-03-15 | 四川科▲倫▼▲薬▼物研究院有限公司 | 注射可能なルラシドン懸濁液及びその製造方法 |
| CN120078778A (zh) * | 2024-09-25 | 2025-06-03 | 山东百诺医药股份有限公司 | 一种伏硫西汀酯药物组合物及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2800953B2 (ja) * | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| KR100537713B1 (ko) | 1997-09-30 | 2005-12-20 | 일라이 릴리 앤드 캄파니 | 2-메틸-티에노-벤조디아제핀 제제 |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| FI105074B (fi) | 1997-12-31 | 2000-06-15 | Leiras Oy | Farmaseuttisen formulaation valmistusmenetelmä |
| PL196821B1 (pl) | 1998-09-30 | 2008-02-29 | Lilly Co Eli | Sól olanzapiny i jej zastosowanie |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| US20040022862A1 (en) | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| WO2002078673A1 (fr) | 2001-03-29 | 2002-10-10 | Takeda Chemical Industries, Ltd. | Procede de production d'un medicament sous forme de granules fins |
| JP4175800B2 (ja) | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | イミド誘導体の製造方法 |
| DE10218110A1 (de) | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| JP4610485B2 (ja) | 2003-07-29 | 2011-01-12 | 大日本住友製薬株式会社 | イミド化合物の製造方法 |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| ATE411797T2 (de) | 2003-10-23 | 2008-11-15 | Otsuka Pharma Co Ltd | Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren |
| AU2005307797B2 (en) | 2004-11-16 | 2011-06-02 | Alkermes Pharma Ireland Limited | Injectable nanoparticulate olanzapine formulations |
| PL1838716T3 (pl) | 2005-01-05 | 2011-09-30 | Lilly Co Eli | Dihydrat embonianu olanzapiny |
| CN101166514A (zh) | 2005-04-13 | 2008-04-23 | 辉瑞产品公司 | 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法 |
| CN102048734B (zh) * | 2005-05-26 | 2013-11-20 | 大日本住友制药株式会社 | 药物组合物 |
| JP4866349B2 (ja) * | 2005-06-13 | 2012-02-01 | 大日本住友製薬株式会社 | 可溶化型製剤 |
| CA2622758A1 (en) | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| WO2007106768A2 (en) | 2006-03-14 | 2007-09-20 | Merck & Co., Inc. | Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use |
| WO2009074666A1 (en) | 2007-12-13 | 2009-06-18 | Novartis Ag | Organic compounds |
-
2011
- 2011-10-18 JP JP2013517506A patent/JP5893616B2/ja not_active Expired - Fee Related
- 2011-10-18 KR KR1020137011618A patent/KR101936968B1/ko not_active Expired - Fee Related
- 2011-10-18 CN CN201710826880.1A patent/CN107595771A/zh active Pending
- 2011-10-18 CA CA2814840A patent/CA2814840C/en not_active Expired - Fee Related
- 2011-10-18 CN CN201180060225.0A patent/CN103249416B/zh not_active Expired - Fee Related
- 2011-10-18 WO PCT/JP2011/074375 patent/WO2012053654A1/en not_active Ceased
- 2011-10-18 CN CN201710826877.XA patent/CN107625728A/zh active Pending
- 2011-10-18 EP EP11834492.8A patent/EP2629775A4/en not_active Withdrawn
- 2011-10-18 US US13/276,039 patent/US9469630B2/en not_active Expired - Fee Related
-
2016
- 2016-02-12 US US15/043,235 patent/US20160158228A1/en not_active Abandoned
- 2016-02-24 JP JP2016033019A patent/JP6173502B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-04 JP JP2017131059A patent/JP6410889B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-12 US US16/128,597 patent/US20190010149A1/en not_active Abandoned
- 2018-09-25 JP JP2018179030A patent/JP2019006822A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543481A5 (https=) | ||
| US9469630B2 (en) | Sustained-release formulation for injection | |
| JP6306609B2 (ja) | 医薬組成物 | |
| KR101053780B1 (ko) | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 | |
| JP2019167377A (ja) | 後眼部へ薬物を送達するための眼用製剤 | |
| CN101322682A (zh) | 难溶性药物纳米粒的制备方法 | |
| JP6225113B2 (ja) | 固体粒子の製造方法 | |
| JP2003535893A5 (https=) | ||
| CN104010661A (zh) | 含有二丁基羟基甲苯的制剂及二丁基羟基甲苯的稳定化方法 | |
| CN102091028A (zh) | 一种依达拉奉注射液及其制备方法 | |
| JP2013144671A (ja) | 眼科用水性組成物 | |
| US20220409588A1 (en) | Oral formulations of edaravone and method of manufacturing thereof | |
| US20200261383A1 (en) | Pharmaceutical compositions | |
| JP6177594B2 (ja) | 水性眼科組成物 | |
| WO2006132342A1 (ja) | ロフルミラスト点眼液 | |
| CZ287115B6 (en) | Agent for ultrasonic diagnostics, ultrasonic contrast medium, set for preparing such contrast medium and process for preparing said agent | |
| CN104586764A (zh) | 一种棕榈酸帕利培酮肌内注射用混悬剂及其制备方法 | |
| CN102266549A (zh) | 一种含有阿加曲班的注射用制剂 | |
| CN102100668B (zh) | 高级脂肪酸衍生物微乳及其制备方法和应用 | |
| JP2007016024A (ja) | ロフルミラスト点眼液 | |
| RU2192855C1 (ru) | Способ получения лекарственного средства для инъекций на основе амиодарона | |
| WO2003099288A1 (en) | Medicinal composition | |
| JP6876017B2 (ja) | オロパタジン含有水性組成物 | |
| WO2021199076A1 (en) | Injectable aripiprazole formulation | |
| CN102204890A (zh) | 复水性能优良的依替巴肽冻干粉针 |